Recursion Pharmaceuticals (RXRX) Financials

$4.08 -0.06 (-1.45%)

Closing price 05/23/2025 04:00 PM Eastern

Extended Trading

$4.09 +0.01 (+0.25%)

As of 05/23/2025 07:59 PM Eastern

Annual Income Statements for Recursion Pharmaceuticals

This table shows Recursion Pharmaceuticals' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric	2024	2023	2022	2021	2020	2019
Period end date	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020	12/31/2019
Net Income / (Loss) Attributable to Common Shareholders	-464	-328	-239	-186	-87	-62
Consolidated Net Income / (Loss)	-464	-328	-239	-186	-87	-62
Net Income / (Loss) Continuing Operations	-464	-328	-239	-186	-87	-62
Total Pre-Tax Income	-465	-332	-239	-186	-85	-62
Total Operating Income	-479	-350	-246	-183	-85	-62
Total Gross Profit	14	1.99	-8.43	10	3.96	2.32
Total Revenue	59	45	40	10	3.96	2.32
Operating Revenue	59	45	40	10	3.96	2.32
Total Cost of Revenue	45	43	48	0.00	0.00	0.00
Operating Cost of Revenue	45	43	48	0.00	0.00	-
Total Operating Expenses	493	352	237	193	89	65
Selling, General & Admin Expense	178	111	82	58	25	19
Research & Development Expense	314	241	156	135	63	46
Total Other Income / (Expense), net	14	18	6.25	-3.70	0.00	0.00
Other Income / (Expense), net	14	18	6.25	-3.70	-	-
Income Tax Expense	-1.13	-4.06	0.00	0.00	-	-
Basic Earnings per Share	($1.69)	($1.58)	($1.36)	($1.49)	($3.99)	($2.87)
Weighted Average Basic Shares Outstanding	274.21M	207.85M	175.54M	125.35M	21.78M	21.57M
Diluted Earnings per Share	($1.69)	($1.58)	($1.36)	($1.49)	($3.99)	($2.87)
Weighted Average Diluted Shares Outstanding	274.21M	207.85M	175.54M	125.35M	21.78M	21.57M
Weighted Average Basic & Diluted Shares Outstanding	401.99M	234.65M	191.23M	170.77M	-	-

This table shows Recursion Pharmaceuticals' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric	Q1 2025	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Period end date	3/31/2025	12/31/2024	9/30/2024	6/30/2024	3/31/2024	12/31/2023	9/30/2023	6/30/2023	3/31/2023	12/31/2022	9/30/2022
Net Income / (Loss) Attributable to Common Shareholders	-202	-179	-96	-98	-91	-93	-93	-77	-65	-57	-60
Consolidated Net Income / (Loss)	-202	-179	-96	-98	-91	-93	-93	-77	-65	-57	-60
Net Income / (Loss) Continuing Operations	-202	-179	-96	-98	-91	-93	-93	-77	-65	-57	-60
Total Pre-Tax Income	-203	-179	-96	-98	-92	-97	-93	-77	-65	-55	-63
Total Operating Income	-191	-184	-98	-101	-96	-99	-100	-82	-70	-61	-63
Total Gross Profit	-7.08	-8.25	14	5.22	2.63	1.01	-0.34	1.64	-0.31	2.84	-2.25
Total Revenue	15	4.55	26	14	14	11	11	11	12	14	13
Operating Revenue	15	4.55	26	14	14	11	11	11	12	14	13
Total Cost of Revenue	22	13	12	9.20	11	9.88	11	9.38	12	11	15
Operating Cost of Revenue	22	13	12	9.20	11	9.88	11	9.38	12	11	15
Total Operating Expenses	184	176	112	106	99	100	99	83	70	64	60
Selling, General & Admin Expense	55	77	38	32	31	30	29	28	23	20	19
Research & Development Expense	130	98	75	74	68	69	70	55	47	44	41
Total Other Income / (Expense), net	-11	4.87	2.68	2.48	4.19	1.87	6.53	4.99	4.54	6.25	0.00
Other Income / (Expense), net	-11	4.87	2.68	2.48	4.19	1.87	6.53	4.99	4.54	-	-
Income Tax Expense	-0.16	0.01	0.17	-0.52	-0.78	-4.06	0.00	0.00	0.00	-	-
Basic Earnings per Share	($0.50)	($0.56)	($0.34)	($0.40)	($0.39)	($0.43)	($0.43)	($0.38)	($0.34)	($0.30)	($0.35)
Weighted Average Basic Shares Outstanding	402.77M	274.21M	282.58M	242.20M	236.02M	207.85M	214.33M	201.42M	191.62M	175.54M	173.44M
Diluted Earnings per Share	($0.50)	($0.56)	($0.34)	($0.40)	($0.39)	($0.43)	($0.43)	($0.38)	($0.34)	($0.30)	($0.35)
Weighted Average Diluted Shares Outstanding	402.77M	274.21M	282.58M	242.20M	236.02M	207.85M	214.33M	201.42M	191.62M	175.54M	173.44M
Weighted Average Basic & Diluted Shares Outstanding	406.50M	401.99M	286.64M	281.11M	237.66M	234.65M	216.62M	215.59M	192.36M	191.23M	189.56M

This table details how cash moves in and out of Recursion Pharmaceuticals' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric	2024	2023	2022	2021	2020	2019
Period end date	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020	12/31/2019
Net Change in Cash & Equivalents	202	-158	264	28	192	59
Net Cash From Operating Activities	-359	-288	-84	-159	-45	-57
Net Cash From Continuing Operating Activities	-359	-290	-84	-159	-45	-57
Net Income / (Loss) Continuing Operations	-464	-328	-239	-186	-87	-62
Consolidated Net Income / (Loss)	-464	-328	-239	-186	-87	-62
Depreciation Expense	36	24	12	8.41	3.94	2.49
Non-Cash Adjustments To Reconcile Net Income	106	66	39	9.77	33	2.88
Changes in Operating Assets and Liabilities, net	-38	-53	104	9.69	4.17	-0.53
Net Cash From Investing Activities	260	-10	193	-272	-8.74	-3.91
Net Cash From Continuing Investing Activities	260	-10	193	-272	-8.74	-3.91
Purchase of Property, Plant & Equipment	-14	-12	-37	-40	-5.83	-3.91
Acquisitions	274	1.25	-0.30	0.00	-3.50	0.00
Sale and/or Maturity of Investments	0.00	0.48	231	69	0.60	0.00
Net Cash From Financing Activities	304	140	154	459	246	120
Net Cash From Continuing Financing Activities	304	140	154	459	246	120
Repayment of Debt	-4.44	-0.77	-0.09	-13	-0.08	-11
Issuance of Common Equity	309	141	154	471	0.68	0.07
Effect of Exchange Rate Changes	-3.41	0.19	-0.31	0.00	0.00	-

This table details how cash moves in and out of Recursion Pharmaceuticals' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric	Q1 2025	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Period end date	3/31/2025	12/31/2024	9/30/2024	6/30/2024	3/31/2024	12/31/2023	9/30/2023	6/30/2023	3/31/2023	12/31/2022	9/30/2022
Net Change in Cash & Equivalents	-94	167	-47	177	-95	4.22	-20	-66	-77	94	0.78
Net Cash From Operating Activities	-132	-115	-59	-82	-102	-74	-73	-67	-73	-45	-55
Net Cash From Continuing Operating Activities	-132	-115	-59	-82	-102	-77	-73	-67	-73	-45	-55
Net Income / (Loss) Continuing Operations	-202	-179	-96	-98	-91	-93	-93	-77	-65	-57	-60
Consolidated Net Income / (Loss)	-202	-179	-96	-98	-91	-93	-93	-77	-65	-57	-60
Depreciation Expense	19	13	7.20	8.97	7.38	7.55	7.58	5.54	3.73	3.21	2.99
Non-Cash Adjustments To Reconcile Net Income	47	67	31	3.98	4.49	56	6.82	2.77	0.55	-114	-2.37
Changes in Operating Assets and Liabilities, net	3.91	-16	-1.25	2.37	-23	-47	5.70	0.95	-12	123	5.29
Net Cash From Investing Activities	-7.27	275	-4.56	-4.18	-6.65	-2.49	-0.35	-2.05	-5.34	-7.98	53
Net Cash From Continuing Investing Activities	-7.27	275	-4.56	-4.18	-6.65	-2.49	-0.35	-2.05	-5.34	-7.98	53
Purchase of Property, Plant & Equipment	-1.83	-1.30	-4.56	-1.18	-6.65	-2.07	-0.75	-3.97	-5.18	-7.98	-8.26
Purchase of Investments	-1.00	-	-	-	-	-	-	-	-	-	-
Divestitures	-4.44	-	-	-	-	-	-	-	-	-	-
Net Cash From Financing Activities	41	11	16	263	14	81	54	3.79	1.92	147	2.34
Net Cash From Continuing Financing Activities	41	11	16	263	14	81	54	3.79	1.92	147	2.34
Repayment of Debt	-2.05	-2.10	-2.29	-0.03	-0.03	-0.69	-0.02	-0.02	-0.02	-0.02	-0.02
Issuance of Common Equity	43	13	19	263	14	81	54	3.81	1.95	147	2.36
Effect of Exchange Rate Changes	4.83	-3.47	0.40	-0.12	-0.22	0.12	-0.12	0.18	-0.00	-0.31	-

This table presents Recursion Pharmaceuticals' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric	2024	2023	2022	2021	2020
Period end date	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020
Total Assets	1,449	654	701	610	299
Total Current Assets	714	438	570	535	266
Cash & Equivalents	594	392	550	285	262
Restricted Cash	3.05	3.23	1.28	1.55	2.00
Accounts Receivable	49	3.09	2.75	9.09	0.16
Other Current Assets	68	40	16	7.51	2.16
Plant, Property, & Equipment, net	141	87	88	65	26
Total Noncurrent Assets	593	129	43	11	6.18
Noncurrent Note & Lease Receivables	26	0.00	-	-	-
Goodwill	149	52	0.80	0.80	0.80
Intangible Assets	336	36	1.31	1.39	1.69
Noncurrent Deferred & Refundable Income Taxes	1.93	0.00	-	-	-
Other Noncurrent Operating Assets	80	41	41	8.72	3.69
Total Liabilities & Shareholders' Equity	1,449	654	701	610	299
Total Liabilities	414	190	215	67	57
Total Current Liabilities	187	93	100	47	23
Short-Term Debt	8.43	0.04	0.10	0.09	1.07
Accounts Payable	22	3.95	4.59	2.82	1.07
Accrued Expenses	82	47	33	32	10
Current Deferred Revenue	62	36	57	10	10
Other Current Liabilities	14	6.12	5.95	1.42	0.47
Total Noncurrent Liabilities	226	97	115	21	33
Long-Term Debt	19	1.10	0.54	0.63	11
Noncurrent Deferred Revenue	119	51	70	11	19
Noncurrent Deferred & Payable Income Tax Liabilities	17	1.34	0.00	-	-
Other Noncurrent Operating Liabilities	72	43	44	0.00	-
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	1,035	463	486	543	-206
Total Preferred & Common Equity	1,035	463	486	543	-206
Total Common Equity	1,035	463	486	543	-206
Common Stock	2,474	1,431	1,125	943	7.31
Retained Earnings	-1,431	-968	-640	-400	-214
Accumulated Other Comprehensive Income / (Loss)	-7.64	0.00	-	-0.13	0.00

This table presents Recursion Pharmaceuticals' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric	Q1 2025	Q3 2024	Q2 2024	Q1 2024	Q3 2023	Q2 2023	Q1 2023	Q3 2022
Period end date	3/31/2025	9/30/2024	6/30/2024	3/31/2024	9/30/2023	6/30/2023	3/31/2023	9/30/2022
Total Assets	1,305	726	776	558	631	667	627	612
Total Current Assets	584	474	522	344	411	431	492	482
Cash & Equivalents	500	428	474	296	387	406	473	455
Restricted Cash	3.08	1.56	1.78	3.20	2.26	3.33	1.31	2.09
Accounts Receivable	46	2.26	2.53	2.60	3.16	3.05	2.06	12
Prepaid Expenses	2.47	-	-	-	-	-	-	-
Other Current Assets	32	43	44	41	18	19	16	13
Plant, Property, & Equipment, net	127	84	84	87	86	90	90	86
Total Noncurrent Assets	594	168	170	128	134	146	45	44
Noncurrent Note & Lease Receivables	25	27	29	-	-	-	-	-
Goodwill	158	52	52	52	53	61	0.80	0.80
Intangible Assets	336	34	38	33	39	43	1.32	1.46
Noncurrent Deferred & Refundable Income Taxes	2.00	-	-	-	-	-	-	-
Other Noncurrent Operating Assets	74	55	51	42	42	43	43	42
Total Liabilities & Shareholders' Equity	1,305	726	776	558	631	667	627	612
Total Liabilities	371	202	191	157	193	198	197	223
Total Current Liabilities	142	109	86	74	94	114	92	83
Short-Term Debt	8.59	8.22	8.11	0.06	0.70	0.68	0.66	0.10
Accounts Payable	25	2.26	3.76	5.12	4.27	2.09	4.25	3.89
Accrued Expenses	57	41	33	26	40	33	25	27
Current Deferred Revenue	40	50	32	37	44	73	58	47
Other Current Liabilities	12	8.23	8.61	6.06	5.36	5.22	4.44	5.54
Total Noncurrent Liabilities	229	93	105	83	99	84	105	140
Long-Term Debt	16	21	23	1.07	1.13	1.16	1.18	0.56
Noncurrent Deferred Revenue	130	16	29	37	51	32	57	94
Noncurrent Deferred & Payable Income Tax Liabilities	22	0.17	0.00	0.53	1.93	4.34	-	-
Other Noncurrent Operating Liabilities	61	57	53	44	44	46	47	46
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	934	525	584	401	438	469	430	388
Total Preferred & Common Equity	934	525	584	401	438	469	430	388
Total Common Equity	934	525	584	401	438	469	430	388
Common Stock	2,553	1,777	1,741	1,460	1,313	1,251	1,135	970
Retained Earnings	-1,634	-1,252	-1,157	-1,059	-875	-782	-705	-582
Accumulated Other Comprehensive Income / (Loss)	14	-	-	-	-	-	-	0.00

This table displays calculated financial ratios and metrics derived from Recursion Pharmaceuticals' official financial filings.

Metric	2024	2023	2022	2021	2020	2019
Period end date	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020	12/31/2019
Growth Metrics	-	-	-	-	-	-
Revenue Growth	32.00%	11.88%	291.46%	156.89%	70.85%	0.00%
EBITDA Growth	-39.18%	-35.13%	-27.88%	-120.74%	-34.56%	0.00%
EBIT Growth	-39.94%	-38.69%	-28.42%	-120.39%	-35.51%	0.00%
NOPAT Growth	-36.83%	-42.46%	-34.44%	-116.01%	-35.51%	0.00%
Net Income Growth	-41.33%	-36.99%	-28.42%	-114.33%	-40.61%	0.00%
EPS Growth	-6.96%	-16.18%	8.72%	62.66%	-39.02%	0.00%
Operating Cash Flow Growth	-24.81%	-244.55%	47.34%	-249.38%	20.41%	0.00%
Free Cash Flow Firm Growth	-92.41%	-424.50%	57.36%	-224.40%	0.00%	0.00%
Invested Capital Growth	566.12%	207.77%	-285.61%	605.01%	0.00%	0.00%
Revenue Q/Q Growth	-9.73%	-5.88%	38.83%	-1.53%	0.00%	0.00%
EBITDA Q/Q Growth	-21.73%	-5.37%	4.69%	-30.84%	0.00%	0.00%
EBIT Q/Q Growth	-21.37%	-6.41%	4.10%	-30.04%	0.00%	0.00%
NOPAT Q/Q Growth	-21.52%	-12.16%	1.59%	-27.46%	0.00%	0.00%
Net Income Q/Q Growth	-22.74%	-12.14%	3.01%	-26.59%	0.00%	0.00%
EPS Q/Q Growth	-8.33%	-8.97%	-44.68%	46.40%	0.00%	0.00%
Operating Cash Flow Q/Q Growth	-13.01%	-11.35%	16.42%	-78.45%	0.00%	0.00%
Free Cash Flow Firm Q/Q Growth	-108.80%	-12.72%	21.89%	0.00%	0.00%	0.00%
Invested Capital Q/Q Growth	274.61%	38.98%	4.84%	147.54%	0.00%	0.00%
Profitability Metrics	-	-	-	-	-	-
Gross Margin	23.12%	4.46%	-21.16%	100.00%	100.00%	100.00%
EBITDA Margin	-727.91%	-690.36%	-571.54%	-1,749.60%	-2,036.14%	-2,585.25%
Operating Margin	-814.09%	-785.33%	-616.74%	-1,795.79%	-2,135.66%	-2,692.58%
EBIT Margin	-789.93%	-745.10%	-601.05%	-1,832.18%	-2,135.66%	-2,692.58%
Profit (Net Income) Margin	-788.02%	-735.99%	-601.05%	-1,832.18%	-2,196.01%	-2,668.35%
Tax Burden Percent	99.76%	98.78%	100.00%	100.00%	102.83%	99.10%
Interest Burden Percent	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%
Effective Tax Rate	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Invested Capital (ROIC)	-125.44%	-9,745.16%	0.00%	-914.59%	0.00%	0.00%
ROIC Less NNEP Spread (ROIC-NNEP)	-98.80%	-9,727.57%	0.00%	-899.13%	0.00%	0.00%
Return on Net Nonoperating Assets (RNNOA)	63.54%	9,676.04%	0.00%	867.08%	0.00%	0.00%
Return on Equity (ROE)	-61.90%	-69.12%	-46.56%	-47.51%	-35.95%	0.00%
Cash Return on Invested Capital (CROIC)	-273.23%	-543.95%	0.00%	-486.55%	0.00%	0.00%
Operating Return on Assets (OROA)	-44.22%	-49.02%	-36.52%	-41.03%	-28.34%	0.00%
Return on Assets (ROA)	-44.11%	-48.42%	-36.52%	-41.03%	-29.14%	0.00%
Return on Common Equity (ROCE)	-61.90%	-69.12%	-46.56%	-20.38%	30.64%	0.00%
Return on Equity Simple (ROE_SIMPLE)	-44.81%	-70.79%	-49.29%	-34.35%	42.18%	0.00%
Net Operating Profit after Tax (NOPAT)	-335	-245	-172	-128	-59	-44
NOPAT Margin	-569.86%	-549.73%	-431.72%	-1,257.05%	-1,494.96%	-1,884.81%
Net Nonoperating Expense Percent (NNEP)	-26.64%	-17.59%	-12.75%	-15.47%	-22.32%	0.00%
Return On Investment Capital (ROIC_SIMPLE)	-31.57%	-52.75%	-35.36%	-	-	-
Cost of Revenue to Revenue	76.88%	95.54%	121.16%	0.00%	0.00%	0.00%
SG&A Expenses to Revenue	302.83%	248.62%	204.80%	566.73%	637.51%	817.21%
R&D to Revenue	534.38%	541.17%	390.77%	1,329.05%	1,598.16%	1,975.38%
Operating Expenses to Revenue	837.21%	789.79%	595.58%	1,895.79%	2,235.66%	2,792.58%
Earnings before Interest and Taxes (EBIT)	-465	-332	-239	-186	-85	-62
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-428	-308	-228	-178	-81	-60
Valuation Ratios	-	-	-	-	-	-
Price to Book Value (P/BV)	1.87	4.61	3.01	5.33	0.00	0.00
Price to Tangible Book Value (P/TBV)	3.52	5.70	3.02	5.35	0.00	0.00
Price to Revenue (P/Rev)	32.93	47.92	36.68	284.42	110.14	188.17
Price to Earnings (P/E)	0.00	0.00	0.00	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	2.94	24.97	0.00	68.42	0.00	0.00
Enterprise Value to Revenue (EV/Rev)	23.25	39.09	22.86	234.51	160.46	0.00
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00	0.00	0.00	0.00
Leverage & Solvency	-	-	-	-	-	-
Debt to Equity	0.03	0.00	0.00	0.02	0.06	0.00
Long-Term Debt to Equity	0.02	0.00	0.00	0.02	0.06	0.00
Financial Leverage	-0.64	-0.99	-1.03	-0.96	-1.03	0.00
Leverage Ratio	1.40	1.43	1.28	1.16	1.23	0.00
Compound Leverage Factor	1.40	1.43	1.28	1.16	1.23	0.00
Debt to Total Capital	2.58%	0.25%	0.13%	1.82%	5.91%	0.00%
Short-Term Debt to Total Capital	0.79%	0.01%	0.02%	0.02%	0.42%	0.00%
Long-Term Debt to Total Capital	1.79%	0.24%	0.11%	1.80%	5.49%	0.00%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	174.29%	0.00%
Common Equity to Total Capital	97.42%	99.75%	99.87%	98.18%	-80.20%	0.00%
Debt to EBITDA	-0.06	0.00	0.00	-0.06	-0.19	0.00
Net Debt to EBITDA	1.33	1.28	2.42	2.85	3.09	0.00
Long-Term Debt to EBITDA	-0.04	0.00	0.00	-0.06	-0.18	0.00
Debt to NOPAT	-0.08	0.00	0.00	-0.08	-0.26	0.00
Net Debt to NOPAT	1.70	1.61	3.20	3.97	4.20	0.00
Long-Term Debt to NOPAT	-0.06	0.00	0.00	-0.08	-0.24	0.00
Altman Z-Score	0.84	3.69	2.53	24.82	3.68	0.00
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%	57.11%	185.24%	0.00%
Liquidity Ratios	-	-	-	-	-	-
Current Ratio	3.81	4.70	5.68	11.46	11.53	0.00
Quick Ratio	3.43	4.24	5.51	11.27	11.35	0.00
Cash Flow Metrics	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	-730	-380	-72	-170	-52	0.00
Operating Cash Flow to CapEx	-2,622.67%	-2,407.19%	-225.38%	-398.55%	-778.58%	-1,458.87%
Free Cash Flow to Firm to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00
Operating Cash Flow to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00
Operating Cash Flow Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00
Efficiency Ratios	-	-	-	-	-	-
Asset Turnover	0.06	0.07	0.06	0.02	0.01	0.00
Accounts Receivable Turnover	2.25	15.25	6.73	2.20	25.40	0.00
Inventory Turnover	0.00	0.00	0.00	0.00	0.00	0.00
Fixed Asset Turnover	0.52	0.51	0.52	0.22	0.15	0.00
Accounts Payable Turnover	3.54	9.97	13.04	0.00	0.00	0.00
Days Sales Outstanding (DSO)	162.09	23.94	54.25	165.79	14.37	0.00
Days Inventory Outstanding (DIO)	0.00	0.00	0.00	0.00	0.00	0.00
Days Payable Outstanding (DPO)	103.14	36.59	27.99	0.00	0.00	0.00
Cash Conversion Cycle (CCC)	58.96	-12.65	26.25	165.79	14.37	0.00
Capital & Investment Metrics	-	-	-	-	-	-
Invested Capital	465	70	-65	35	-6.91	0.00
Invested Capital Turnover	0.22	17.73	-2.67	0.73	-1.15	0.00
Increase / (Decrease) in Invested Capital	395	135	-100	42	-6.91	0.00
Enterprise Value (EV)	1,368	1,742	911	2,387	636	0.00
Market Capitalization	1,938	2,136	1,461	2,895	436	436
Book Value per Share	$3.61	$2.14	$2.56	$3.21	($9.47)	$0.00
Tangible Book Value per Share	$1.92	$1.73	$2.55	$3.20	($9.59)	$0.00
Total Capital	1,062	465	486	553	257	0.00
Total Debt	27	1.14	0.63	10	15	0.00
Total Long-Term Debt	19	1.10	0.54	9.97	14	0.00
Net Debt	-570	-394	-551	-508	-249	0.00
Capital Expenditures (CapEx)	14	12	37	40	5.83	3.91
Debt-free, Cash-free Net Working Capital (DFCFNWC)	-62	-50	-82	-30	-20	0.00
Debt-free Net Working Capital (DFNWC)	535	345	470	488	244	0.00
Net Working Capital (NWC)	527	345	470	488	243	0.00
Net Nonoperating Expense (NNE)	128	83	67	59	28	18
Net Nonoperating Obligations (NNO)	-570	-394	-551	-508	-249	0.00
Total Depreciation and Amortization (D&A)	36	24	12	8.41	3.94	2.49
Debt-free, Cash-free Net Working Capital to Revenue	-105.67%	-111.70%	-204.67%	-294.40%	-497.60%	0.00%
Debt-free Net Working Capital to Revenue	909.64%	773.99%	1,178.74%	4,796.13%	6,168.88%	0.00%
Net Working Capital to Revenue	895.32%	773.90%	1,178.50%	4,795.24%	6,141.80%	0.00%
Earnings Adjustments	-	-	-	-	-	-
Adjusted Basic Earnings per Share	($1.69)	($1.58)	($1.36)	($1.49)	$0.00	$0.00
Adjusted Weighted Average Basic Shares Outstanding	274.21M	207.85M	175.54M	125.35M	0.00	0.00
Adjusted Diluted Earnings per Share	($1.69)	($1.58)	($1.36)	($1.49)	$0.00	$0.00
Adjusted Weighted Average Diluted Shares Outstanding	274.21M	207.85M	175.54M	125.35M	0.00	0.00
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	401.99M	234.65M	191.23M	170.77M	0.00	0.00
Normalized Net Operating Profit after Tax (NOPAT)	-335	-245	-172	-128	-59	-44
Normalized NOPAT Margin	-569.86%	-549.73%	-431.72%	-1,257.05%	-1,494.96%	-1,884.81%
Pre Tax Income Margin	-789.93%	-745.10%	-601.05%	-1,832.18%	-2,135.66%	-2,692.58%
Debt Service Ratios	-	-	-	-	-	-
EBIT to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00
NOPAT to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00
EBIT Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00
NOPAT Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00
Payout Ratios	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%

This table displays calculated financial ratios and metrics derived from Recursion Pharmaceuticals' official financial filings.

Metric	Q1 2025	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Period end date	3/31/2025	12/31/2024	9/30/2024	6/30/2024	3/31/2024	12/31/2023	9/30/2023	6/30/2023	3/31/2023	12/31/2022	9/30/2022
Growth Metrics	-	-	-	-	-	-	-	-	-	-	-
Revenue Growth	6.89%	-58.26%	147.62%	30.86%	13.68%	-20.36%	-19.96%	43.56%	127.53%	439.91%	419.34%
EBITDA Growth	-116.24%	-85.41%	-3.56%	-25.16%	-37.62%	-54.94%	-43.39%	-12.27%	-15.76%	7.90%	-35.52%
EBIT Growth	-119.90%	-84.32%	-2.86%	-27.81%	-41.06%	-59.16%	-48.65%	-15.92%	-16.70%	6.12%	-34.85%
NOPAT Growth	-98.64%	-85.75%	1.20%	-23.04%	-37.89%	-62.23%	-59.09%	-23.45%	-24.80%	6.12%	-34.85%
Net Income Growth	-121.60%	-92.38%	-3.04%	-27.13%	-39.87%	-61.75%	-53.89%	-17.03%	-16.70%	11.46%	-27.45%
EPS Growth	-28.21%	-30.23%	20.93%	-5.26%	-14.71%	-43.33%	-22.86%	0.00%	-3.03%	-350.00%	-25.00%
Operating Cash Flow Growth	-28.99%	-55.82%	18.78%	-21.87%	-39.53%	-65.54%	-33.70%	-9.48%	-194.74%	26.83%	-65.04%
Free Cash Flow Firm Growth	-128.87%	-156.98%	24.06%	25.14%	-102.85%	-457.82%	-590.22%	-516.81%	-248.98%	165.26%	182.32%
Invested Capital Growth	343.24%	566.12%	147.13%	126.23%	342.11%	207.77%	173.79%	177.90%	56.85%	-285.61%	-582.84%
Revenue Q/Q Growth	224.35%	-82.57%	80.91%	4.52%	26.66%	3.40%	-4.39%	-9.21%	-11.28%	3.92%	71.49%
EBITDA Q/Q Growth	-10.47%	-87.56%	0.69%	-5.10%	7.23%	-4.76%	-20.03%	-15.56%	-6.63%	3.05%	6.03%
EBIT Q/Q Growth	-13.27%	-86.99%	2.44%	-6.41%	6.85%	-4.34%	-21.23%	-17.45%	-7.13%	2.54%	5.47%
NOPAT Q/Q Growth	-4.14%	-86.84%	2.18%	-4.36%	2.62%	0.62%	-21.83%	-16.96%	-14.57%	2.54%	5.47%
Net Income Q/Q Growth	-13.18%	-86.67%	1.74%	-6.75%	1.75%	0.02%	-21.23%	-17.45%	-13.63%	4.89%	7.80%
EPS Q/Q Growth	10.71%	-64.71%	15.00%	-2.56%	9.30%	0.00%	-13.16%	-11.76%	-13.33%	14.29%	7.89%
Operating Cash Flow Q/Q Growth	-14.32%	-94.90%	27.97%	19.63%	-38.10%	-1.59%	-8.08%	7.98%	-63.84%	17.96%	11.49%
Free Cash Flow Firm Q/Q Growth	7.07%	-266.92%	3.65%	30.33%	-4.34%	-8.43%	5.02%	-88.77%	-284.06%	48.55%	-19.24%
Invested Capital Q/Q Growth	-2.02%	274.61%	-10.96%	35.62%	47.25%	38.98%	-18.49%	245.14%	34.46%	4.84%	13.95%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-	-
Gross Margin	-48.04%	-181.43%	53.69%	36.19%	19.05%	9.28%	-3.27%	14.84%	-2.59%	20.74%	-17.09%
EBITDA Margin	-1,243.23%	-3,650.40%	-339.23%	-617.99%	-614.58%	-821.83%	-811.16%	-646.12%	-507.66%	-422.40%	-452.77%
Operating Margin	-1,297.85%	-4,042.39%	-377.10%	-697.39%	-698.42%	-908.36%	-945.12%	-741.72%	-575.78%	-445.91%	-475.48%
EBIT Margin	-1,374.33%	-3,935.28%	-366.82%	-680.19%	-668.06%	-891.18%	-883.10%	-696.43%	-538.38%	-445.91%	-475.48%
Profit (Net Income) Margin	-1,373.26%	-3,935.46%	-367.46%	-676.56%	-662.41%	-853.88%	-883.10%	-696.43%	-538.38%	-420.39%	-459.31%
Tax Burden Percent	99.92%	100.00%	100.17%	99.47%	99.15%	95.81%	100.00%	100.00%	100.00%	105.04%	96.60%
Interest Burden Percent	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	89.75%	100.00%
Effective Tax Rate	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Invested Capital (ROIC)	-194.62%	-622.86%	-197.44%	-241.16%	-749.53%	-11,271.92%	0.00%	0.00%	0.00%	0.00%	0.00%
ROIC Less NNEP Spread (ROIC-NNEP)	-176.98%	-612.43%	-190.59%	-234.78%	-743.32%	-11,266.89%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Net Nonoperating Assets (RNNOA)	102.98%	393.89%	156.08%	189.99%	689.39%	11,207.20%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Equity (ROE)	-91.64%	-228.97%	-41.36%	-51.16%	-60.14%	-64.72%	-70.84%	-57.36%	-53.87%	-46.56%	-50.03%
Cash Return on Invested Capital (CROIC)	-270.34%	-273.23%	-401.38%	-352.83%	-397.81%	-543.95%	-670.65%	-541.04%	0.00%	0.00%	0.00%
Operating Return on Assets (OROA)	-88.21%	-220.28%	-35.23%	-46.81%	-52.12%	-58.63%	-67.33%	-51.99%	-36.88%	-27.09%	-21.49%
Return on Assets (ROA)	-88.14%	-220.29%	-35.29%	-46.56%	-51.68%	-56.18%	-67.33%	-51.99%	-36.88%	-25.54%	-20.76%
Return on Common Equity (ROCE)	-91.64%	-228.97%	-41.36%	-51.16%	-60.14%	-64.72%	-70.84%	-57.36%	-53.87%	-46.56%	-50.03%
Return on Equity Simple (ROE_SIMPLE)	-61.54%	0.00%	-72.01%	-64.15%	-88.27%	0.00%	-66.80%	-55.44%	-57.84%	0.00%	-63.63%
Net Operating Profit after Tax (NOPAT)	-134	-129	-69	-70	-67	-69	-70	-57	-49	-43	-44
NOPAT Margin	-908.50%	-2,829.67%	-263.97%	-488.17%	-488.89%	-635.86%	-661.59%	-519.20%	-403.05%	-312.13%	-332.84%
Net Nonoperating Expense Percent (NNEP)	-17.64%	-10.43%	-6.85%	-6.37%	-6.21%	-5.03%	-5.53%	-4.23%	-3.09%	-2.80%	-3.20%
Return On Investment Capital (ROIC_SIMPLE)	-13.97%	-12.11%	-	-	-	-14.91%	-	-	-	-8.78%	-
Cost of Revenue to Revenue	148.04%	281.43%	46.31%	63.81%	80.95%	90.72%	103.27%	85.16%	102.59%	79.26%	117.09%
SG&A Expenses to Revenue	370.63%	1,697.89%	144.76%	220.80%	227.69%	279.67%	277.21%	256.79%	188.51%	145.06%	148.09%
R&D to Revenue	879.17%	2,163.07%	286.02%	512.78%	489.78%	637.98%	664.64%	499.77%	384.68%	321.59%	310.30%
Operating Expenses to Revenue	1,249.81%	3,860.95%	430.78%	733.59%	717.47%	917.65%	941.86%	756.56%	573.19%	466.64%	458.39%
Earnings before Interest and Taxes (EBIT)	-203	-179	-96	-98	-92	-97	-93	-77	-65	-61	-63
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-183	-166	-88	-89	-85	-90	-85	-71	-62	-58	-60
Valuation Ratios	-	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	2.28	1.87	3.53	3.05	5.83	4.61	3.77	3.06	2.97	3.01	4.75
Price to Tangible Book Value (P/TBV)	4.83	3.52	4.23	3.61	7.40	5.70	4.77	3.93	2.98	3.02	4.77
Price to Revenue (P/Rev)	35.57	32.93	28.42	35.91	50.60	47.92	34.82	28.75	27.35	36.68	64.17
Price to Earnings (P/E)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	3.62	2.94	11.70	9.60	19.86	24.97	25.12	16.71	0.00	0.00	0.00
Enterprise Value to Revenue (EV/Rev)	27.56	23.25	22.28	26.94	44.15	39.09	26.64	20.60	17.21	22.86	48.27
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-	-
Debt to Equity	0.03	0.03	0.05	0.05	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to Equity	0.02	0.02	0.04	0.04	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Financial Leverage	-0.58	-0.64	-0.82	-0.81	-0.93	-0.99	-1.02	-1.02	-1.15	-1.03	-1.05
Leverage Ratio	1.40	1.40	1.41	1.37	1.43	1.43	1.50	1.48	1.47	1.28	1.29
Compound Leverage Factor	1.40	1.40	1.41	1.37	1.43	1.43	1.50	1.48	1.47	1.14	1.29
Debt to Total Capital	2.61%	2.58%	5.19%	5.04%	0.28%	0.25%	0.41%	0.39%	0.43%	0.13%	0.17%
Short-Term Debt to Total Capital	0.90%	0.79%	1.49%	1.32%	0.01%	0.01%	0.16%	0.14%	0.15%	0.02%	0.02%
Long-Term Debt to Total Capital	1.71%	1.79%	3.71%	3.72%	0.27%	0.24%	0.26%	0.25%	0.27%	0.11%	0.14%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	97.39%	97.42%	94.81%	94.96%	99.72%	99.75%	99.59%	99.61%	99.57%	99.87%	99.83%
Debt to EBITDA	-0.05	-0.06	-0.08	-0.09	0.00	0.00	-0.01	-0.01	-0.01	0.00	0.00
Net Debt to EBITDA	0.91	1.33	1.14	1.28	0.90	1.28	1.33	1.57	2.00	2.42	1.91
Long-Term Debt to EBITDA	-0.03	-0.04	-0.06	-0.07	0.00	0.00	0.00	0.00	-0.01	0.00	0.00
Debt to NOPAT	-0.06	-0.08	-0.10	-0.11	0.00	0.00	-0.01	-0.01	-0.01	0.00	0.00
Net Debt to NOPAT	1.19	1.70	1.45	1.61	1.13	1.61	1.77	2.12	2.60	3.20	2.61
Long-Term Debt to NOPAT	-0.04	-0.06	-0.07	-0.08	0.00	0.00	-0.01	-0.01	-0.01	0.00	0.00
Altman Z-Score	1.62	1.50	3.35	3.82	6.42	4.87	3.38	2.98	2.80	3.37	4.10
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-	-
Current Ratio	4.11	3.81	4.35	6.07	4.65	4.70	4.36	3.78	5.34	5.68	5.80
Quick Ratio	3.85	3.43	3.95	5.54	4.04	4.24	4.15	3.59	5.16	5.51	5.62
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	-487	-524	-143	-148	-213	-204	-188	-198	-105	57	38
Operating Cash Flow to CapEx	-7,202.89%	-8,892.91%	-1,298.22%	-6,955.92%	-1,537.65%	-3,583.79%	-9,787.92%	-1,700.28%	-1,416.73%	-560.82%	-660.06%
Free Cash Flow to Firm to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Operating Cash Flow to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Operating Cash Flow Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.06	0.06	0.10	0.07	0.08	0.07	0.08	0.07	0.07	0.06	0.05
Accounts Receivable Turnover	2.45	2.25	24.06	17.80	19.86	15.25	6.40	6.79	6.93	6.73	4.12
Inventory Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Fixed Asset Turnover	0.56	0.52	0.76	0.57	0.52	0.51	0.55	0.58	0.58	0.52	0.41
Accounts Payable Turnover	3.70	3.54	12.97	14.06	8.82	9.97	10.68	18.27	12.59	13.04	7.33
Days Sales Outstanding (DSO)	148.72	162.09	15.17	20.51	18.38	23.94	57.03	53.78	52.64	54.25	88.50
Days Inventory Outstanding (DIO)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Days Payable Outstanding (DPO)	98.60	103.14	28.14	25.95	41.36	36.59	34.18	19.97	29.00	27.99	49.80
Cash Conversion Cycle (CCC)	50.12	58.96	-12.96	-5.45	-22.99	-12.65	22.85	33.81	23.64	26.25	38.69
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-	-
Invested Capital	455	465	124	139	103	70	50	62	-42	-65	-68
Invested Capital Turnover	0.21	0.22	0.75	0.49	1.53	17.73	-5.31	-5.72	-0.66	-2.67	-1.06
Increase / (Decrease) in Invested Capital	353	395	74	78	145	135	118	141	56	-100	-82
Enterprise Value (EV)	1,648	1,368	1,452	1,337	2,041	1,742	1,261	1,030	803	911	1,385
Market Capitalization	2,127	1,938	1,853	1,782	2,339	2,136	1,649	1,437	1,276	1,461	1,842
Book Value per Share	$2.32	$3.61	$1.87	$2.46	$1.71	$2.14	$2.03	$2.44	$2.25	$2.56	$2.24
Tangible Book Value per Share	$1.09	$1.92	$1.56	$2.08	$1.35	$1.73	$1.60	$1.90	$2.24	$2.55	$2.23
Total Capital	959	1,062	553	615	402	465	440	471	432	486	389
Total Debt	25	27	29	31	1.13	1.14	1.82	1.83	1.84	0.63	0.66
Total Long-Term Debt	16	19	21	23	1.07	1.10	1.13	1.16	1.18	0.54	0.56
Net Debt	-478	-570	-400	-445	-298	-394	-388	-407	-473	-551	-456
Capital Expenditures (CapEx)	1.83	1.30	4.56	1.18	6.65	2.07	0.75	3.97	5.18	7.98	8.26
Debt-free, Cash-free Net Working Capital (DFCFNWC)	-53	-62	-56	-32	-30	-50	-72	-91	-74	-82	-58
Debt-free Net Working Capital (DFNWC)	451	535	374	444	270	345	317	318	401	470	399
Net Working Capital (NWC)	442	527	365	436	270	345	316	317	400	470	399
Net Nonoperating Expense (NNE)	69	50	27	27	24	24	23	20	16	15	17
Net Nonoperating Obligations (NNO)	-478	-570	-400	-445	-298	-394	-388	-407	-473	-551	-456
Total Depreciation and Amortization (D&A)	19	13	7.20	8.97	7.38	7.55	7.58	5.54	3.73	3.21	2.99
Debt-free, Cash-free Net Working Capital to Revenue	-88.27%	-105.67%	-85.45%	-63.91%	-64.39%	-111.70%	-153.04%	-182.96%	-158.26%	-204.67%	-202.30%
Debt-free Net Working Capital to Revenue	753.89%	909.64%	573.00%	895.34%	583.43%	773.99%	669.55%	635.64%	858.92%	1,178.74%	1,389.12%
Net Working Capital to Revenue	739.53%	895.32%	560.39%	879.00%	583.31%	773.90%	668.08%	634.29%	857.51%	1,178.50%	1,388.79%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	($0.50)	($0.56)	($0.34)	($0.40)	($0.39)	($0.43)	($0.43)	($0.38)	($0.34)	($0.30)	($0.35)
Adjusted Weighted Average Basic Shares Outstanding	402.77M	274.21M	282.58M	242.20M	236.02M	207.85M	214.33M	201.42M	191.62M	175.54M	173.44M
Adjusted Diluted Earnings per Share	($0.50)	($0.56)	($0.34)	($0.40)	($0.39)	($0.43)	($0.43)	($0.38)	($0.34)	($0.30)	($0.35)
Adjusted Weighted Average Diluted Shares Outstanding	402.77M	274.21M	282.58M	242.20M	236.02M	207.85M	214.33M	201.42M	191.62M	175.54M	173.44M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	406.50M	401.99M	286.64M	281.11M	237.66M	234.65M	216.62M	215.59M	192.36M	191.23M	189.56M
Normalized Net Operating Profit after Tax (NOPAT)	-134	-129	-69	-70	-67	-69	-70	-57	-49	-43	-44
Normalized NOPAT Margin	-908.50%	-2,829.67%	-263.97%	-488.17%	-488.89%	-635.86%	-661.59%	-519.20%	-403.05%	-312.13%	-332.84%
Pre Tax Income Margin	-1,374.33%	-3,935.28%	-366.82%	-680.19%	-668.06%	-891.18%	-883.10%	-696.43%	-538.38%	-400.21%	-475.48%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
NOPAT to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
EBIT Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
NOPAT Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Payout Ratios	-	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%

Frequently Asked Questions About Recursion Pharmaceuticals' Financials

When does Recursion Pharmaceuticals's financial year end?

According to the most recent income statement we have on file, Recursion Pharmaceuticals' fiscal year ends in December. Their fiscal year 2024 ended on December 31, 2024.

How has Recursion Pharmaceuticals' net income changed over the last 5 years?

Recursion Pharmaceuticals' net income appears to be on an upward trend, with a most recent value of -$463.66 million in 2024, rising from -$61.88 million in 2019. The previous period was -$328.07 million in 2023. See Recursion Pharmaceuticals' forecast for analyst expectations on what’s next for the company.

What is Recursion Pharmaceuticals's operating income?

Recursion Pharmaceuticals's total operating income in 2024 was -$479.00 million, based on the following breakdown:

Total Gross Profit: $13.60 million
Total Operating Expenses: $492.61 million

How has Recursion Pharmaceuticals revenue changed over the last 5 years?

Over the last 5 years, Recursion Pharmaceuticals' total revenue changed from $2.32 million in 2019 to $58.84 million in 2024, a change of 2,437.3%.

How much debt does Recursion Pharmaceuticals have?

Recursion Pharmaceuticals' total liabilities were at $413.82 million at the end of 2024, a 117.5% increase from 2023, and a 631.6% increase since 2020.

How much cash does Recursion Pharmaceuticals have?

In the past 4 years, Recursion Pharmaceuticals' cash and equivalents has ranged from $262.13 million in 2020 to $594.35 million in 2024, and is currently $594.35 million as of their latest financial filing in 2024.

How has Recursion Pharmaceuticals' book value per share changed over the last 5 years?

Over the last 5 years, Recursion Pharmaceuticals' book value per share changed from 0.00 in 2019 to 3.61 in 2024, a change of 361.0%.

Related Companies

This page (NASDAQ:RXRX) was last updated on 5/25/2025 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Recursion Pharmaceuticals (RXRX) Financials

Frequently Asked Questions About Recursion Pharmaceuticals' Financials

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Recursion Pharmaceuticals (RXRX) Financials

Annual Income Statements for Recursion Pharmaceuticals

Quarterly Income Statements for Recursion Pharmaceuticals

Annual Cash Flow Statements for Recursion Pharmaceuticals

Quarterly Cash Flow Statements for Recursion Pharmaceuticals

Annual Balance Sheets for Recursion Pharmaceuticals

Quarterly Balance Sheets for Recursion Pharmaceuticals

Annual Metrics And Ratios for Recursion Pharmaceuticals

Quarterly Metrics And Ratios for Recursion Pharmaceuticals

Frequently Asked Questions About Recursion Pharmaceuticals' Financials

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools